Table 7.
Trial feature | Kruskal-Wallis | P | RCTs | Subgrouping (medians) | ||
---|---|---|---|---|---|---|
Dropout | Trial characteristic | Publication date | X2(1) = 10.73 | 0.001 | 414 | 2009 or before (3%)* |
2010 or after (9%) | ||||||
Trial size | X2(4) = 25.38 | < 0.001 | 414 | 21 or fewer (0%)* | ||
22–34 participants (7%) | ||||||
35–60 participants (8%) | ||||||
61–99 participants (8%) | ||||||
100 ore more (8%) | ||||||
Recruitment characteristic | Continent of recruitment | X2(2) = 11.91 | 0.003 | 354 | Europe (7%) | |
Asia (2%) | ||||||
North America (8%) | ||||||
Recruitment Strategy | X2(2) = 6.09 | 0.048 | 205 | Screening stroke survivors in the community (9%) | ||
Screening admissions (8%) | ||||||
Screening inpatients (3%)* |
* Least dropout
Kruskal–Wallis = appropriate statistics for Kruskal–Wallis test, p = significance level, RCTs = number of RCTs contributing to this finding